John Lacey - BioLine RX Head Relations

BLRX Stock  ILS 8.10  0.10  1.25%   

Insider

John Lacey is Head Relations of BioLine RX
Phone(972) 8 642 9101
Webwww.biolinerx.com

BioLine RX Management Efficiency

The company has return on total asset (ROA) of (0.2029) % which means that it has lost $0.2029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3721) %, meaning that it generated substantial loss on money invested by shareholders. BioLine RX's management efficiency ratios could be used to measure how well BioLine RX manages its routine affairs as well as how well it operates its assets and liabilities.
BioLine RX has accumulated 10.69 M in total debt with debt to equity ratio (D/E) of 23.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioLine RX has a current ratio of 5.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BioLine RX until it has trouble settling it off, either with new capital or with free cash flow. So, BioLine RX's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLine RX sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLine to invest in growth at high rates of return. When we think about BioLine RX's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Yvonne NaughtonCompugen
N/A
Michel HabibEnlivex Therapeutics
52
Brian SchwartzEnlivex Therapeutics
57
Henry MDCompugen
58
Rivka SchwartzCompugen
N/A
Liat WejgmanEvogene
N/A
Yaron EldadEvogene
58
Shai NovikEnlivex Therapeutics
53
Lilach TopilskyKamada
N/A
Eyal RonenEvogene
N/A
Eran NirKamada
50
Odelia BenShitritEnlivex Therapeutics
N/A
Ari ShamissKamada
N/A
Ofer CPAEvogene
57
Oliver FroescheisCompugen
57
Elran MBAEvogene
43
Sangwoo LeeEnlivex Therapeutics
47
Bernhard KirschbaumEnlivex Therapeutics
60
Dotan BorensteinEvogene
N/A
Dorit AmitayCompugen
55
Jon KnightKamada
N/A
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people. BioLine RX (BLRX) is traded on Tel Aviv Stock Exchange in Israel and employs 38 people.

Management Performance

BioLine RX Leadership Team

Elected by the shareholders, the BioLine RX's board of directors comprises two types of representatives: BioLine RX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLine. The board's role is to monitor BioLine RX's management team and ensure that shareholders' interests are well served. BioLine RX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLine RX's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Chief Officer
Ella Sorani, Vice President - Development
Raziel Fried, Treasurer Director
Jael MSc, QA RA
CPA MBA, Chief Officer
Holly MBA, Pres USA
Advocate Kotler, Gen Officer
Liron MBA, Director Devel
John Lacey, Head Relations
Abi MD, Chief Officer
LLB BSc, Head Advisor

BioLine Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLine RX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BioLine Stock

BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.